POLICY

1. Purpose

1.1. Describe the responsibilities and requirements of a Principal Investigator (PI) to ensure research is conducted in accordance with the Office for Human Subject Protection (OHSP) and University policies and guidelines, as well as federal regulations, as applicable.

1.1.1. To ensure that the rights, safety, and welfare of research subjects are protected during the conduct of the research study and after the research study is completed.

1.1.2. To ensure the integrity of the data collected during the conduct of the research study.

2. Scope

This policy applies to any individual designated as a Principal Investigator conducting human subject research governed by the Research Subjects Review Board (RSRB) under the University of Rochester Human Research Protection Program.

Note: For research review that is deferred to another IRB, responsibilities and requirements defined herein are also deferred to that IRB; however, institutional responsibilities to the UR still apply. See Policy 504 RSRB Review Reliance.

3. Definitions

3.1. Principal Investigator – An individual who meets the qualifications and requirements outlined in the University of Rochester “Principal Investigator Eligibility Policy” (regardless of funding source) and who has the full and final responsibility for the conduct of the approved research.

3.1.1. A Principal Investigator on a proposal reviewed by the RSRB with an exempt determination need not hold a faculty position (e.g., students).

3.1.2. Individuals not meeting the criteria include: adjunct professors, residents, fellows, students or staff members, even if they are identified as the Principal Investigator by the funding source or regulatory body (e.g., NIH/NSF grant, FDA-approved Investigational New Drug application, Investigational Device Exemption). Such individuals may serve as a Co-Principal Investigator under the aegis of a UR-recognized and approved PI who assumes ultimate responsibility for the research.

3.2. Sponsor-Investigator – An individual who initiates and conducts a clinical investigation, and has the direct oversight of the administration, dispensing and/or use of the test item (e.g., holds the IND/IDE).

4. References

4.1. HHS 45 CFR 46; FDA 21 CFR 56; FDA 21 CFR 50; FDA 21 CFR 312; FDA 21 CFR 812; FDA Guidance for Industry Investigator Responsibilities
4.2. University of Rochester Principal Investigator Eligibility Policy;
University of Rochester Clinical Research Billing Policy;
UR Clinical Research Standard Operating Procedures Regarding Financial Oversight and Billing Compliance;
Policy for Scientific Review for Human Subjects Research;
Policy 501 Levels of RSRB Review;
Policy 502 Types of RSRB Submissions;
Policy 503 Ancillary Committee Reviews;
Policy 504 RSRB Review Reliance;
Policy 605 Research Using FDA Regulated Drugs or Biologics;
Policy 606 Research Using FDA Regulated Devices;
Policy 701 Informed Consent Process;
Policy 702 HIPAA Privacy Rule;
Policy 801 Reporting Research Events

4.3. Guideline for Investigators Leaving the Institution;
Guideline for Reporting Research Events;
RSRB Protocol Templates;
OHSP Study Documentation Tool Box;
Summary of Responsibilities for Investigators Conducting EXEMPT Research;
Summary of Responsibilities for Investigators Conducting Non FDA-Regulated Research;
Summary of Responsibilities for Investigators Conducting FDA-Regulated Research

5. Responsibilities

Responsibilities are described within the Principal Investigator requirements under Sections 6 – 9 below, as well as the Summary of Responsibility documents listed under Section 4.3 above.

6. Requirements for All Principal Investigators

6.1. Oversee the conduct of all research activities, including the training and education of research staff (as applicable).

6.1.1. PIs may delegate responsibilities and functions of research activities to appropriately trained and capable research staff; however, the PI must document this delegation and must maintain all oversight responsibilities.

6.2. Obtain scientific review of the proposed research (see Scientific Review for Human Subjects Research policy) prior to submission to the RSRB.

6.3. Provide a research protocol that contains sufficient information to meet the standards established by federal and state regulations, University policies, and to ensure an effective review by the RSRB (see RSRB Protocol Templates).
6.3.1. For studies supported by grant funds, a separate protocol must be submitted in addition to the grant proposal, as the grant does not provide sufficient detail to substitute for the RSRB research protocol.

6.4. Implement and conduct research in compliance with federal and state regulations, the Office for Human Subject Protection (OHSP) and University policies and guidelines, the ethical principles and standards appropriate for the PI’s discipline, and determinations of the RSRB, only after the following conditions have been met:

6.4.1. RSRB approval is obtained (or a review determination as applicable);
6.4.2. Required ancillary committee approvals are obtained, as applicable, according to Policy 503 Ancillary Committee Reviews;
6.4.3. For research involving the use or disclosure of protected health information (PHI), the protection of subjects’ privacy and confidentiality is in compliance with Policy 702 HIPAA Privacy Rule; and,
6.4.4. For sponsored research, a fully executed contract is in place before enrolling subjects.

6.5. Individuals who mentor a non-faculty Investigator (e.g., student, resident, fellow) are also responsible for the following:

6.5.1. Advise the non-faculty Investigator throughout protocol development, submission to RSRB, and implementation of the research protocol, as appropriate.
6.5.2. Ensure the non-faculty Investigator meets appropriate training and education requirements regarding human subject research.
6.5.3. Ensure the non-faculty Investigator is aware of and meets the responsibilities and requirements of this policy as an Investigator.
6.5.4. Conduct activities necessary to maintain appropriate oversight and guidance for the non-faculty Investigator during the conduct of the research.
6.5.5. Ensure the non-faculty Investigator research activity is closed in a timely fashion.

7. Requirements for Principal Investigators Conducting Research Exempt from Federal Regulations

In addition to the requirements listed under Section 6 above, the following apply to Investigators conducting research that is exempt from federal regulations (see Policy 501 Levels of RSRB Review):

7.1. Maintain documentation to support RSRB determination of materials reviewed.

7.1.1. For exempt research this includes, at minimum, the finalized protocol, the RSRB application, and the RSRB letter regarding the exempt determination.

7.2. Use consent forms (or information letters) bearing a current “RSRB Approved” watermark with the first page printed on UR letterhead.
7.2.1. For research including the requirement for signed consent, study documentation includes all pages of the original signed consent form for at least 3 years after the research is completed (6 years if HIPAA Authorization used as part of the research).

7.3. Conduct research in compliance with the finalized RSRB approved protocol, and submit any changes to the research (protocol or other study materials) for review and approval by the RSRB prior to implementation of those changes.

7.4. Obtain approval of recruitment materials and/or recruitment methods prior to use and/or implementation, at the time of initial RSRB review or during the conduct of the study.

7.5. Ensure that subjects’ questions, concerns, and complaints are properly addressed and that resolution to any of these reports is documented and retained in the study record. Report concerns and complaints per the Guideline for Reporting Research Events.

7.6. Report research events according to Policy 801 Reporting Research Events and the Guideline for Reporting Research Events.

8. Requirements for Principal Investigators Conducting Non-FDA Regulated Research

In addition to the requirements listed under Sections 6 and 7 above, the following apply to Investigators conducting non-FDA regulated greater than minimal risk or minimal risk research:

8.1. If applicable, be knowledgeable with the UR Clinical Research Billing Policy and the UR Clinical Research Standard Operating Procedures Regarding Financial Oversight and Billing Compliance, and successfully complete the required Blackboard training course CT-01 “Overview of Clinical Research Billing Policy and Standard Operating Procedures” in order to ensure compliance with regard to the following activities (refer to the Office of Research and Project Administration Clinical Trial Resources for related materials):
   8.1.1. Development of a budget, independent of the sponsor (if applicable);
   8.1.2. Oversight of expenditure completeness and accuracy, and revenue realization (if there is a sponsor);
   8.1.3. Timely programmatic and financial closeout.

8.2. Maintain a regulatory file with current and accurate records of all study documentation as required by applicable regulatory requirements (see OHSP Quality Improvement Study Documentation Tool Box for regulatory file guidance).
8.3. Conduct RSRB approved research in compliance with Department of Health and Human Services (HHS) regulations 45 CFR 46.

8.4. Obtain and document informed consent according to Policy 701 Informed Consent Process, unless the requirements for consent or documentation of consent have been waived or altered.

8.5. Obtain and document HIPAA authorization according to Policy 702 HIPAA Privacy Rule, unless the requirements for authorization or documentation of authorization have been waived or altered.

8.6. Ensure the data and safety monitoring plan outlined in the approved protocol is followed. This includes timely submission of data and safety monitoring reports, as applicable, per the Guideline for Reporting Research Events.

8.7. Ensure timely submission of the progress report for continuing review well in advance of the expiration date to ensure continued RSRB approval during the conduct of the study (see Policy 502 Types of RSRB Submissions).

8.7.1. If RSRB approval of the study expires, ensure all research activities (including recruitment, enrollment, interventions, interactions, and data analysis on current subjects) are stopped.

8.8. Submit a final continuing review report when a study is completed or closed.

8.9. When new information or findings related to subject safety or welfare are identified after a study has closed, provide the RSRB with a report of the new information/findings.

8.10. Notify the RSRB if departing the University (temporarily or permanently) and follow additional procedures according to the Guideline for Investigators Leaving the Institution.

9. Requirements for Principal Investigators Conducting FDA Regulated Research

In addition to the requirements listed under Sections 6, 7 and 8 above, the following apply to Investigators conducting greater than minimal risk or minimal risk research regulated by the Food and Drug Administration (FDA):

9.1. Conduct the approved research in compliance with FDA regulations 21 CFR 56 and 21 CFR 50, as well as to oversee (or delegate as appropriate) the control of drugs,
biologics or medical devices under investigation based on the use of such FDA regulated products: drugs and biologics [21 CFR 312], devices [21 CFR 812].

9.1.1. Conduct research involving an Investigational New Drug (IND), Investigational Device Exemption (IDE), or abbreviated IDE in compliance with Policy 605 Research Using FDA Regulated Drugs or Biologics and Policy 606 Research Using FDA Regulated Devices, as applicable.

9.2. Conduct the approved research according to the FDA “Guidance for Industry – Investigator Responsibilities”.

9.3. Maintain all pages of the signed consent form(s) in the study file for at least 3 years after the research is completed (6 years if HIPAA Authorization used as part of the research), or for a longer term if required by FDA regulations or other contractual agreements.

9.4. Investigators with the role of sponsor-investigator will comply with the responsibilities and requirements for both the “Investigator” and “Sponsor” defined by the FDA [21 CFR 312].
Originator/Authors:
Emily Flagg, Senior Regulatory Specialist

Appendices:
None

Revision History:
None

Supersedes Date:
Not Applicable

Approved By:

Robert Clark
Institutional Official and Senior VP for Research

8/25/14
Date

Stephen Dewhurst
Associate Vice President for Health Sciences Research

8/26/2014
Date

Karl Kieburitz
Senior Associate Dean for Clinical Research

Date

Harriet Kitzman
Senior Associate Dean for Research, School of Nursing

Date

David Williams
Dean for Research of Arts, Science, & Engineering

Date

(signatures continued next page)

Page 7 of 8
Originator/Authors:
Emily Flagg, Senior Regulatory Specialist

Appendices:
None

Revision History:
None

Supersedes Date:
Not Applicable

Approved By:

Robert Clark
Institutional Official and Senior VP for Research

Date

Stephen Dewhurst
Associate Vice President for Health Sciences Research

8/28/14

Date

Karl Kieburutz
Senior Associate Dean for Clinical Research

Date

Harriet Kitzman
Senior Associate Dean for Research, School of Nursing

Date

David Williams
Dean for Research of Arts, Science, & Engineering

8/27/14

Date

(signatures continued next page)

Paper copies of the Policy may not be the current version. The current version of this Policy is maintained and available on the OHSP shared network.
<table>
<thead>
<tr>
<th>University of Rochester</th>
<th>Office for Human Subject Protection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Research Subjects Review Board</td>
</tr>
<tr>
<td></td>
<td>Investigator Responsibilities</td>
</tr>
<tr>
<td>Effective Date: 08/22/2014</td>
<td>Policy 901</td>
</tr>
<tr>
<td>Version: 1.0</td>
<td></td>
</tr>
</tbody>
</table>

| Kelley A. O'Donoghue   | 8/26/2014 |
| Director, OHSP         | Date      |

| Tiffany L. Gommel      | 8/26/2014 |
| Director, RSRB         | Date      |

Paper copies of the Policy may not be the current version. The current version of this Policy is maintained and available on the OHSP shared network.